Baby nutritional compositions intended for prevention of adiposity

FIELD: food industry.

SUBSTANCE: invention relates to prevention of baby adiposity at a later stage of one's life. One proposes application of a specified composition in alimentation of a baby not suffering from adiposity at an age of no less than 36 months. The composition contains a lipid component, a protein component and a component consisting of digestible carbohydrates. The lipid component includes: linoleic acid (LA) and alfa-linolenic acid (ALA), the weight ratio of LA/ALA being 2 - 7; less than 14.5 wt % of LA in conversion to total weight of fatty acids; 2 wt % - 10 wt % of ALA in conversion to total weight of fatty acids, 0.02 - 0.8 wt % of n-6 long chain polyunsaturated fatty acids (LC-PUFA) in conversion to total weight of fatty acids and 0.2 wt % - 15 wt % of n-3 LC-PUFA in conversion to total weight of fatty acids. The weight ratio of n-6 LC-PUFA to n-3 LC-PUFA is 1.5.

EFFECT: invention allows to prevent occurrence of adiposity at a later stage of one's life.

14 cl, 5 tbl, 4 ex

 

The technical field to which the invention relates

The present invention relates to the prevention of obesity at a later stage of life by the introduction of a specific nutrient compositions babies, not suffering from obesity, aged less than 3 years.

The level of technology

Breastfeeding is the preferred method of infant feeding. However, there are circumstances in which breastfeeding is not possible or desirable. In such cases, a good alternative is a mixture of baby food. The modern composition of mixtures adapted in such a way that meet specific nutrient needs for rapid growth and development of the baby.

Despite this there is still a need to improve the composition of milk powder for baby food. For example, little is known about the effects of ingredients of a mixture for baby food on obesity at a later stage of life. The present invention relates to such health in the future.

In WO 2005063050 describes how to increase muscle mass and reduce body fat mass in infants the introduction of a baby born at term or prematurely, a mixture of baby food, including the source of DHA and ARA. In WO 2006057551 described children's nutrition, including at least diningout protease, the method of obtaining such baby food and child nutrition for the treatment and/or prevention of childhood obesity and secondary illness as a result of childhood obesity. In WO 03005836 described dietetic products for infants, children and adults with adequate levels and ratios of medium chain fatty acids and omega-polyunsaturated fatty acids. The consumption of these diet products contributes to the prevention of obesity in developing individuals and contributes to the reduction of body fat mass in individuals trying to lose weight or reduce body fat body mass (for example, individuals with obesity). In WO 2006069918 describes the way the continuous reduction of the level of circulating insulin-like growth factor 1 (IGF-1) in the first few months of the baby's life the introduction of infant nutritional composition comprising protein in such amounts that the composition contains less than about 2.25 g of protein per 100 kcal. Because IGF-1 is known as a key control point in the nutritional regulation of growth, this may be a way of reducing the risk of developing obesity at a later stage of life. In the document "Aillaud et al., 2006, Progress in Lipid research 45:203-206", describes the role of n-6 polyunsaturated fatty acids in excessive adipose tissue development and in conjunction with obesity.

Disclosure of invention

In the ore age, body fat, in particular subcutaneous fat serves an important function in maintaining adequate body temperature and energy storage. In addition, as a rule, reduced body fat mass in infants is undesirable, because it may harm the normal growth and development. Therefore, the main purpose of the present invention is to provide nutrition for the baby, which guarantees the maintenance of normal body weight, growth and development during infancy, but at the same time reduces the deposition of excess body fat at a later stage of life (i.e. after infancy), preferably in adolescence and/or adulthood.

The authors of the present invention experimentally found that the introduction in the early stages of the life power, the lipid component which contains a relatively low amount of linoleic acid (LA) and which has a low ratio of linoleic acid/alpha-linolenic acid (LA/ALA), leads to a decrease in the accumulation of fat mass, in particular to reduce the accumulation of visceral fat mass at a later stage of life. In these experiments, mice received a special diet (low LA and low ratio of LA/ALA) in the early stages of life, while the control group received no special power. At a later stage of life of a group of animals received the same the initial diet with high saturated fat content. Unexpectedly, it was found that there has been no impact on the growth and overall body body weight in infants, but in comparison with the control group in the young and Mature age, total body fat and visceral fat mass was reduced in mice fed the experimental diet in infancy. The experimental results indicate the impact of nutritional compositions for infants on the development of obesity at a later stage of life, particularly in the age of 36 months, i.e. in childhood (ages 3-12 years), adolescence (age 13-18 years) and adulthood (age 18 years).

Therefore, the present invention relates to a method of preventing the development of obesity in infants older than 36 months, in other words, the prevention of obesity at a later stage of life. This method includes the introduction of a baby aged less than 36 months, the nutritional composition containing a lipid component, a protein component and a component consisting of digestible carbohydrates, where the lipid component comprises linoleic acid (LA) and alpha linolenic acid (ALA) in a weight ratio of LA/ALA from 2 to 7; less than 15 wt.% LA by weight of the total fatty acids; and at least 1 wt.% ALA by weight of the total fatty acids. Also the present invention relates to the use of a composition containing a lipid component is, the protein component and a component consisting of digestible carbohydrates, where the lipid component includes (i) linoleic acid (LA) and alpha linolenic acid (ALA) in a weight ratio of LA/ALA from 2 to 7; (ii) less than 15 wt.% LA by weight of the total fatty acids; and (iii)at least 1 wt.% ALA by weight of the total fatty acids, to obtain the nutritional composition (not suffering from obesity) infant aged less than 36 months, designed to prevent obesity. The present invention preferably relates to compositions for food not suffering from obese person aged less than 36 months, where the specified composition comprises a lipid component, a protein component and a component consisting of digestible carbohydrates, where the lipid component comprises linoleic acid (LA) and alpha linolenic acid (ALA) in a weight ratio of LA/ALA from 2 to 7; less than 15 wt.% LA by weight of the total fatty acids; and more than 1 wt.% ALA by weight of the total fatty acids, and is intended to prevent the development of disorders, particularly obesity, when the person is over the age of 36 months.

However, the introduction of a mixture of baby food with low content of LA in the present invention may lead to shortages. The authors of the present invention have found that the inclusion of medium chain fatty acids (MCFA) in the composition is Yu of the present invention with a low LA baby aged less than 36 months has the advantage to reduce or overcome the deficit of fat due to low injection LA. LA is an essential fatty acid, which means the impossibility of its formation in the body. Because the composition of the present invention includes a relatively low content of LA, it is important that LA, which is part of the composition of the present invention, is not converted into energy (fat oxidation) and, therefore, not available for anabolic purposes. To reduce oxidation in LA composition with a low content of LA in the present invention can be introduced MCFA. MCFA can be easily mobilized into the bloodstream to ensure long-term energy instead to secede as fat, and therefore they reduce oxidation of LA. Additionally, it has been unexpectedly found that a composition rich in medium chain fatty acids (MCFA) also reduces fat mass of the body at a later stage of life, without effects on body composition and growth during infancy. However, MCFA not only reduces the accumulation of visceral fat mass, but also leads to a decrease in the accumulation of total fat mass at a later stage of life. The inclusion of MCFA, thus, prevents the deficiency of LA and has a positive impact on obesity at a later stage of life. Therefore, MCFA are in limited quantities in the composition of the present invention.

Will add the flax authors of the present invention have found, the development of nutrition for babies with low levels of LA and low ratio of LA/ALA to prevent obesity at a later stage of life may reduce the bioavailability and break embedding LA and n-6 long-chain polyunsaturated fatty acids (LC-PUFA), biosynthesizing of LA, such as arachidonic acid (BA), in the membranes of nerve tissue such as brain tissue and the retina. This introduction is very important for babies, in particular for the development of the visual system, brain, intellect and cognitive skills at a later stage of life. Therefore, as alternative ways of preventing side effects compositions with a low content of LA in the present invention it was found that the introduction of n-6 LC-PUFA, in particular BA, in the composition of the present invention for an infant aged less than 36 months has the advantage. In addition, it was found that the diet enrichment of n-3 LC-PUFA, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), also results in a decrease in total body fat mass (at a later stage of life), without affecting overall body body weight and growth in infancy. Therefore, n-3 LC-PUFA also mostly administered in the composition to reduce the development of obesity at a later stage of life. An additional objective of the present invention is the I provision of a composition with a low content of LA, low insulin response.

Detailed description of the invention

The present invention relates to the use of a composition containing a lipid component, a protein component and a component consisting of digestible carbohydrates, where the lipid component includes:

(i) linoleic acid (LA) and alpha linolenic acid (ALA) in a weight ratio of LA/ALA from 2 to 7;

(ii) less than 15 wt.% LA by weight of the total fatty acids; and

(iii) at least 1 wt.% ALA by weight of the total fatty acids,

and where the composition further comprises at least one component selected from the group consisting of:

(a) from 3 to 50 wt.% medium chain fatty acids (MCFA) of the total mass of fatty acids;

and

(b) n-6 long-chain polyunsaturated fatty acids (LC-PUFA) and n-3 LC-PUFA in a mass ratio of less than 1.5; from 0.02 to 0.8 wt.% n-6 LC-PUFA of the total mass of fatty acids and at least 0.2 wt.% n-3 LC-PUFA by weight of the total fatty acids;

to obtain the nutritional composition (not suffering from obesity) infant aged less than 36 months intended for the prevention of obesity.

Obesity

The composition of the present invention is administered to the infant, not suffering from obesity, in the age of less than 36 months, preferably less than 18 months, more preferably less than 12 months, even more preferably less than 6 month is. Preferably the composition of the present invention is administered to a person without overweight, aged less than 36 months, preferably less than 18 months, more preferably less than 12 months, even more preferably less than 6 months. The presence or absence of obesity and/or overweight in infants can be identified by a doctor using a suitable method. Typically, an infant aged less than 36 months, not suffering from obesity has a gender ratio of the mass to rise less than 95 percentile, more preferably less than 85 percentile. The gender ratio of the mass to growth was published by the Center for control and prevention of diseases of the United States (Center for Disease Control and Prevention, CDC) in 2000. Similarly, the presence or absence of obesity and/or overweight the subject has aged more than 36 months can easily be determined by a physician and/or gender ratio of the mass to growth, published by the CDC. Problems related to health generally associated with specific forms of obesity, namely with common obesity. Preferably the composition is used for the prevention of common obesity at a later stage of life. Used herein, the term "total obesity" refers to a condition with increased visceral fat mass. A waist circumference more than 102 cm in an adult male or waist circumference Bo is her 88 cm for adult women indicates the total obesity. For children 3-19 years appropriate within the waist, depending on age and gender can be found in Taylor et al., 2000, Am J Clin Nutr 72:490-495".

Composition with a low content of LA

In the present invention LA refers to linoleic acid (18:2 n6); ALA refers to α-linolenic acid (18:3 n3); LC-PUFA refers to long-chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain having 2 or more unsaturated linkages; DHA refers to docosahexaenoic acid (22:6, n3); EPA refers to eicosapentaenoic acid (20:5 n3); ARA refers to arachidonic acid (20:4 n6); DPA applies to docosapentaenoic acid (22:5 n3), and DHGLA refers to dihomogammalinolenic acid (20:3 n6). Medium chain fatty acids (MCFA) are fatty acids and/or acyl chain length of 6, 8 or 10 carbon atoms. MCFA can also refer to the medium chain triglycerides (MCT).

The authors of the present invention have discovered that certain compositions with a low ratio of LA/ALA and low in LA have a preventive effect on obesity, in particular on General obesity. In particular, the introduction of a nutritional composition, comprising (i) LA/ALA mass ratio of from 2 to 7, and (ii) low LA content (<15 wt.% by weight of the total fatty acids)results in a reduction of the structure of obesity at a later stage of life.

The composition according to the present invention includes a lipid. LA must be present in sufficient quantity to maintain a healthy growth, but as soon as a minimum number to prevent obesity at a later stage of life. In addition, the composition contains less than 15 wt.% LA by weight of the total fatty acids, preferably less than 14.5 wt.% or from 5 to 14.5 wt.%, more preferably from 6 to 12 wt.%. The composition according to the present invention preferably contains from 1.5 to 5 wt.% LA of the total dry weight of the composition. In the case of liquid forms, such as ready-to-use mixture for baby food, the LA content is preferably from 0.2 to 0.55 g LA per 100 ml liquid composition. LA provides preferably from 4 to 8% of the total calories of the composition of the present invention.

ALA must be present in sufficient quantity to maintain healthy growth and development of the baby. In addition, the composition according to the present invention contains at least 1.0 wt.% ALA by weight of the total fatty acids. Preferably the composition contains at least 1.6 wt.% ALA by weight of the total fatty acids, more preferably at least 2.0 wt.%. Preferably the composition comprises less than 10 wt.% ALA, more preferably less than 5,0, wt.% by weight of the total fatty acids. The composition on this is th invention preferably includes, at least 0.10 wt.% ALA, preferably from 0.10 to 0.8 wt.% ALA of the total dry weight of the composition. In the case of a liquid form of the composition, for example ready-to-use mixture for baby food, the ALA content is preferably at least 30 mg of ALA per 100 ml liquid composition, preferably from 50 to 150 mg ALA per 100 ml liquid composition.

The mass ratio of LA/ALA must be well balanced to prevent obesity, particularly morbid obesity, ensuring normal growth and development. The authors of the present invention has identified its own value. The composition according to the present invention contains LA/ALA mass ratio of from 2 to 7, more preferably from 3 to 6, even more preferably from 4 to 5.5, even more preferably from 4 to 5. The liquid component comprises less than 15 wt.% LA by weight of the total fatty acids, and the ratio of LA/ALA ranges from 2 to 7.

MCFA and LC-PUFA

It was found that n-3 LC-PUFA reduces the risk of both types of obesity, as visceral and General obesity at a later stage of life, and it was found that MCFA reduce the risk of General obesity at a later stage of life. This discovery contributes to the optimal composition, preferably containing MCFA, but not in excessive amounts, then e is th from 3 to 50 wt.% from the total mass of fatty acids and/or LC-PUFA, including n-6 LC-PUFA, but with a low ratio of n-6 LC-PUFA/n-3 LC-PUFA.

Medium chain fatty acids (MCFA) are fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. Also, the authors of the present invention found that MCFA contribute to the reduction of fat mass at a later stage of life. LA is an essential fatty acid, which means the impossibility of its formation in the body. Because the composition of the present invention includes a relatively low content of LA, it is important that LA, which is part of the composition of the present invention, is not converted into energy (fat oxidation) and, therefore, not available for anabolic purposes. To reduce oxidation in LA composition with a low content of LA in the present invention can be introduced MCFA. MCFA can be easily mobilized into the bloodstream to provide energy instead to secede as fat and, therefore, reduce the oxidation of LA. Therefore, the composition of the present invention contains at least 3 wt.% MCFA by weight of the total fatty acids, more preferably at least 10 wt.%, even more preferably 15 wt.%.

The authors of the present invention found that MCFA reduce the deposition of body fat, without preference in relation to the mass of visceral fat. Sledovat is Ino, composition with a low LA and low ratio of LA/ALA according to the present invention mainly contains less than 50 wt.% MCFA by weight of the total fatty acids, more preferably less than 40 wt.%, even more preferably less than 25 wt.%.

Preferably the composition according to the present invention includes a LC-PUFA. The authors of the present invention found that LC-PUFA reduces obesity at a later stage of life, more preferably the total obesity. More preferably the composition according to the present invention includes n-3 LC-PUFA, even more preferably EPA, DPA and/or DHA, more preferably DHA. It was found that these n-3 LC-PUFA reduce obesity.

Because DHA, DPA and/or EPA in low concentrations are effective for normal growth and development, it is important that the content of n-3 LC-PUFA in the composition of the present invention preferably does not exceed 15 wt.% of the total fatty acids, preferably not more than 10 wt.%, even more preferably does not exceed 5 wt.%. Preferably the composition according to the present invention contains at least 0.2 wt.%, preferably, at least 0.5 wt.%, more preferably at least 0.75 wt.% n-3 LC-PUFA of the total content of fatty acids. For the same reason, the EPA content preferably does not exceed 5 wt.% from the total mass of fatty acids, Bo is it preferably does not exceed 1 wt.%, but preferably is at least, of 0.025 wt.%, more preferably is at least, of 0.05 wt.% by weight of the total fatty acids. The DHA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, but is preferably at least 0.1 wt.% by weight of the total fatty acids. The DPA content preferably does not exceed 1 wt.%, more preferably does not exceed 0.5 wt.% of the total fatty acids, but is preferably at least 0.01 wt.% by weight of the total fatty acids. Preferably as a source of n-3 LC-PUFA used oil unicellular, preferably algal oil, fungal oil, and/or microbial oil, because these sources are oils have a low ratio of EPA/DHA, which increases the impact of anti-obesity. More preferably the composition according to the present invention includes fish oil (preferably fat tuna). Fish oil may have a higher concentration of EPA, which is an advantage, because EPA is a precursor of eicosanoids, which have additional effects against obesity.

As the group of n-6 fatty acids, in particular arachidonic acid (AA), and LA as its predecessor counteracts the group of n-3 fatty acids, in particular DHA, EPA and ALA, as their predestin is the IKI, the composition according to the present invention includes a relatively low amount of AA. The content of n-6 LC-PUFA preferably does not exceed 5 wt.%, more preferably does not exceed 0.8 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.% by weight of the total fatty acids. Because AA is important for optimal functioning of membranes in infants, in particular membranes of nerve tissue, the amount of n-6 LC-PUFA is preferably at least 0.02 wt.%, more preferably, at least, of 0.05 wt.%, even more preferably, at least 0.1 wt.% by weight of the total fatty acids, more preferably at least 0.25 wt.%. The composition according to the present invention preferably contains less than 1 wt.% AA by weight of the total fatty acids. The presence of AA is an advantage in compositions with a low content of LA, eliminating the deficit, LA. The presence of preferably low amounts of AA is positive in the diet for introducing babies aged less than 6 months, because these babies, as a rule, the power source is the only infant formula.

The mass ratio of n-6 LC-PUFA/n-3 LC-PUFA in infant nutrition for babies of the present invention is preferably low to prevent obesity at a later stage is isni. Preferably the composition includes a mass ratio of n-6 LC-PUFA/n-3 LC-PUFA less than 1.5; more preferably less than 1.0; more preferably less than 0.6. LA, ALA, MCFA and/or LC-PUFA is preferably present as free fatty acids in the form of triglycerides in the form of diglyceride, in the form of monoglyceride, in the form of a phospholipid or a mixture of one or more of the above. Preferably the composition according to the present invention contains LC-PUFA in the form of a triglyceride and/or phospholipid, more preferably in the form of a phospholipid, because the LC-PUFA in the form of phospholipid better embedded in the membrane. Preferably the composition according to the present invention contains MCFA in the form of triglycerides.

Table 1 lists the desirable characteristics of the lipid component of the composition of the present invention.

Table 1
preferably, themore preferablymost preferably
LA (wt.% by weight of the total fatty acids)<155-14,56-12
ALA (wt.% by weight of the total fatty acids) >1the 1.6-102,0-5,0
The mass ratio of LA/ALA2-73-64-5,5
MCFA (wt.% by weight of the total fatty acids)3-5010-4015-25
n-6 LC-PUFA (wt.% from the total mass of fatty acids, the amount of AA+DHGLA)0,02-0,80,05-0,750,25-0,5
n-3 LC-PUFA (wt.% from the total mass of fatty acids, the sum of EPA+DPA and DHA)>0,20.25 to 150,75-5
The ratio of n-6 LC-PUFA/n-3 LC-PUFA<1,5<1,0<0,6

Preferably the composition according to the present invention includes at least one, preferably at least two sources of lipids selected from the group consisting of Flaxseed oil (linseed oil), rapeseed oil (including rapeseed oil, rapeseed oil, low erucic acid and canola oil), oil of Dalmatian sage, perelomova oil, oil purslane, oil b is usnike, sea-buckthorn oil, hemp oil, sunflower oil with a high content of olein, olive oil, marine oils, microbial oils, oils of black currant, the echium oil, milk fat, coconut oil and palm kernel oil. Preferably the composition according to the present invention includes at least one, preferably at least two sources of lipids selected from the group consisting of Flaxseed oil, rapeseed oil, coconut oil, sunflower oil with a high content of olein, milk fats and marine oils.

Phospholipids, cholesterol and sphingolipids

Since LA, which represents an essential fatty acid, and n-6 LC-PUFA are essential components of membranes, including the membranes of nerve tissue), a small amount of LA and optional n-6 LC-PUFA is present in the composition according to the present invention, preferably embedded in the membranes of nerve cells, as effectively as possible. This can be achieved by using the lipid components of the membrane, including cholesterol, phospholipids and/or sphingolipids in the composition of the present invention with a low content of LA. The presence of these components increases the embeddability PUFA, including LA and n-6 LC-PUFA in the membrane, thus reducing oxidation. Used herein, the term "phospholipids", the particular refers to glycerophosphates. Glycerophosphate are a class of lipids derived from fatty acid esterification on the hydroxyl groups of 1 carbon atom and 2 carbon atoms of the main molecule of glycerin, and a negatively charged phosphate group attached to the 3-carbon atom of glycerol through the ester linkage and optional Kalinovo group (in the case of phosphatidylcholine), serine group (in the case of phosphatidylserine), ethanolamine group (in the case of phosphatidylethanolamine), Inositol group (in the case of phosphatidylinositol), or glycerol group (in the case of phosphatidylglycerol) attached to a phosphate group. Preferably the composition according to the present invention contains phosphatidylcholine (PC), phosphatidylserine, phosphatidylinositol and/or phosphatidylethanolamine, more preferably at least phosphatidylcholine.

The preferred source of phospholipids, in particular PC is soy lecithin, egg lipid and/or milk fat. Therefore, the composition of the present invention preferably includes soy lecithin, egg lipid and/or milk fat, more preferably soy lecithin and/or milk fat. Preferably the composition according to the present invention includes from 0.5 to 20 wt.% phospholipids by weight of the total lipids, more preferably from 1 to 10 wt.%, even more preferred is sustained fashion from 4 to 8 wt.%. The authors present invention also found that oral administration of compositions comprising phospholipids, and/or sphingolipids, and/or cholesterol, has an additional advantage in reducing the insulin response after a meal (see Example 2). High levels of insulin stimulate the consumption of glucose from adipose tissue, resulting in increases in body fat. In infants high insulin levels also contribute to the increased proliferation of visceral fat cells, at least partly due to the increased consumption of glucose. Preferably the composition according to the present invention includes from 0.5 to 20 wt.% of sphingolipids by weight of the total lipids, more preferably from 1 to 10 wt.%, even more preferably 4 to 8 wt.%. Used herein, the term "sphingolipids" refers to the glycolipids with aminosterol by sphingosine. Frame sphingosine through the oxygen atom is linked to (usually) saturated head group, such as ethanolamine, serine or choline. The backbone through amide linked fatty acyl group. Sphingolipids include sphingomyelin, ceramides and glycosphingolipids. Preferably the composition according to the present invention contains sphingomyelin and/or glycosphingolipids. Glycosphingolipids are ceramides with one or more sugar residue linked β-GL is cosignee communication 1 hydroxyl position. Glycophospholipid can be further subdivided into the cerebrosides, globosides and gangliosides. The cerebrosides have a single glucose or galactose in position 1 hydroxyl group, while gangliosides have at least three of sugar, one of whom must be a sialic acid. Sphingomyelin contain a molecule of phosphorylcholine or phosphorothiolates, esterified on the hydroxyl group in position 1 of ceramide. Preferably the composition according to the present invention contains gangliosides.

Preferably the composition contains sphingolipids, more preferably sphingomyelin and/or gangliosides. Preferably the composition according to the present invention contains at least one ganglioside selected from the group consisting of GM3 and GD3. Preferably, the composition according to the present invention contains from 0.5 to 20 wt.% (sphingolipids plus phospholipids) by weight of the total lipids, more preferably from 1 to 10 wt.%, even more preferably 4 to 8 wt.%.

Dietary cholesterol modulates lipid metabolism through stimulation of chain elongation of fatty acyl chains (phospholipids, free fatty acids; diglycerides and triglycerides). Through the conversion of essential fatty acids in their LC-PUFA increases the production of essential building blocks for the construction of member and, therefore, the synthesis and function of nerve membranes of the brain. Thus, the use of essential lipids for energy metabolism decreases. In addition, cholesterol is an essential building block of membranes and are needed to increase the synthesis of membranes. Therefore, to prevent side effects from a mixture of baby food with low content of LA in the composition with a low content of LA in the present invention mainly included cholesterol. In addition, dietary cholesterol in infancy inhibits the synthesis of endogenous cholesterol and programs the synthesis of endogenous cholesterol to lower levels. Therefore, at a later stage of life can be achieved lowered cholesterol levels in the blood. This leads to the drop of LDL-cholesterol and increased HDL-cholesterol in adolescence and adulthood. Therefore, the present invention also relates to the use of a composition comprising a lipid, protein, digestible carbohydrate and cholesterol to obtain the nutritional composition introduced to the infant aged less than 36 months for the prevention of cardiovascular diseases, atherosclerosis, and/or high level of cholesterol in the blood at a later stage of life. Preferably, this nutritional composition comprises at least part of the neo is required nutrients, as described in the present application, for example mainly includes not digestible oligosaccharides, lactose and/or lipid component, as described above.

Preferred sources of cholesterol are milk fat, non-fat buttermilk, non-fat cheese butter and egg lipids. Therefore, the composition of the present invention preferably includes fat buttermilk, non-fat cheese butter and/or egg lipids. The composition according to the present invention preferably includes at least 0.005 wt.% cholesterol from total fat mass, more preferably at least 0.01 wt.%, more preferably, at least, of 0.05 wt.%, even more preferably, at least 0.1 wt.%. Preferably the amount of cholesterol does not exceed 10 wt.% by weight of the total lipids, more preferably does not exceed 5 wt.%, even more preferably does not exceed 1 wt.% from the total mass of lipids. Most preferably the amount of cholesterol is from 0.5 to 0.7 wt.% from the total mass of lipids. Preferably the amount of cholesterol does not exceed 1 wt.% from total fat mass, more preferably the amount of cholesterol does not exceed 0.5 wt.%.

The uridine and choline

Alternatively, a composition with a low content of LA in the present invention includes a source of uridine and choline. People treated composition with h skim content of LA in the present invention, increased synthesis of membranes made preferably by the presence of two main precursor for phosphatidylcholine or other major phospholipids of the membranes of the brain, namely the source of uridine and choline. The uridine is metabolized to cytidine and subsequently fosfauriliruetsa to CTP; choline is metabolized to phosphocholine. Therefore, CTP and phosphocholine in the lead to the formation of CDP-choline, a key step in the biosynthesis pathway of phospholipid. Therefore, the combination of a source of uridine and choline stimulates the biosynthesis of phospholipids. Increased synthesis of phospholipids caused by the fact that the addition of uridine and choline also enhances the incorporation of arachidonic acid and other LC-PUFA in the main phospholipids of the brain that makes this addition to being suitable to neutralize the side effects of the composition with a low content of LA in the present invention.

Preferably the composition includes a source of uridine and choline. Choline, preferably introduced as choline chloride. The composition according to the present invention preferably includes at least a 0.035 wt.% choline by weight of the total dry matter of the composition, more preferably, at least, of 0.045 wt.%. Preferably the composition according to the present invention includes not less than 1 wt.% choline by weight of the total dry matter of the composition or more preferably is, less than 0.5 wt.%, even more preferably less than 0.1 wt.%. The presence of choline has the additional advantage that lies in the oxidation of fat, which in result leads to an increase in lean body mass and increases the clearance of blood lipids in cells. Choline has the additional advantage consists in the fact that he is an excellent donor bromide. At the stage of rapid growth, such as infancy, a sufficient number of methyl donor it is important to support differentiation and regulation and, therefore, leads to its own metabolic imprinting through DNA methylation. Own metabolic imprinting is important for the prevention of obesity at a later stage of life. Therefore, the composition of the present invention preferably includes choline.

In a preferred variant embodiment of the present invention, the composition includes the uridine in the form of a nucleotide, nucleoside and/or Foundation. Preferably the composition according to the present invention includes from 0.001 to 0.1 wt.% uridine of the total dry weight of the composition, more preferably from 0.002 to 0.05 wt.%, most preferably from 0.002 to 0.025 wt.%. More preferably, the composition includes the uridine in the form of the nucleotide. Preferably the uridine is a monophosphate, diphosphate or trifosfatnogo f the RMU nucleotide more preferably, the monophosphate form of the nucleotide. Originalia nucleotides can be monomers, dimers or polymers (including RNA). Preferably the nucleotides are present in the form of the free acid or in salt form, preferably in the form of salts monolatry. Preferably the composition according to the present invention includes a 5'-monophosphate uridine and/or its salt (have a common abbreviation UMP), in particular salts monolatry. Preferably the composition according to the present invention includes from 0.001 to 0.1 wt.% UMP of the total dry weight of the composition, more preferably from 0.002 to 0.05 wt.%, most preferably from 0.002 to 0.025 wt.%. UMP is preferably introduced into the composition in the form of a mixture of nucleotides. Preferably the composition according to the present invention contains RNA of yeast as the source of the UMP. Preferably the composition includes UMP and choline. Preferably the composition includes a source of uridine, choline and phospholipids. Preferably the composition includes UMP, choline and phospholipids. This combination also stimulates the formation of membranes and, therefore, essentially suitable for inclusion in a composition with a low content of LA in the present invention.

Not digestible oligosaccharides

As mentioned above, high levels of insulin in the blood stimuliresponsive glucose from fatty tissue, which in result leads to an increase in the mass of adipose tissue. In infants, high levels of insulin contribute to the increased proliferation of fat cells, at least partially due to the increased consumption of glucose and, therefore, increases the chances of obesity at a later stage of life.

The composition of the present invention therefore preferably provides a low insulin levels. It was found that not digestible oligosaccharides (NDO), which can be fermented (in particular, galactooligosaccharide), have a normalizing effect on the insulin levels in the blood and, therefore, contribute to reducing the risk of obesity at a later stage of life. In addition, it was also found that babies who are bottle feeding, you absorb more calories compared with infants who are breastfed. In addition to the compositional characteristics of the lipid component of the present invention can be further improved efficiency by reducing calorie intake. The dose limit nutrient composition, however, is practically not acceptable for babies. The authors of the present invention have found that for this purpose, mainly the composition of the present invention includes not assimilated the oligosaccharides.

Fermentation of these non-digestible oligosaccharides, preferably of galactooligosaccharides, additionally, the result leads to the formation of acetate in the intestine, which is consumed and enters the blood stream and the liver, which is an advantage as it is a precursor elongation of lipid and/or predominantly stimulates the conversion of LA to AA.

Therefore, the composition of the present invention preferably comprises a lipid component and is not digestible oligosaccharide, which can be fermented. Combination lipid component and is not digestible oligosaccharides according to the present invention synergistically reduces the risk of obesity at a later stage of life. Preferably the composition according to the present invention includes not digestible oligosaccharides with degree of polymerization (SP) from 2 to 60. Preferably the composition prevents insulin resistance. Not digestible oligosaccharide is preferably selected from the group consisting of fructo-oligosaccharides (including inulin), galactooligosaccharides (including transplantological), glucooligosaccharides (including, gentio, Niger and cyclodextringlucosyl), arabinopyranoside, mannanoligosaccharides, xylooligosaccharides, focalisation, arabinogalactans, glucoronolactone is in, galactopyranoside, oligosaccharides containing sialic acid and oligosaccharides, including uronic acid. Preferably the composition according to the present invention includes fructo-oligosaccharides, galactooligosaccharides and/or oligosaccharides comprising galacturonic acid, more preferably galactooligosaccharide, most preferably transplantological. In preferred embodiments, embodiments of the present invention, the composition includes a mixture of transplantationfollow and fructo-oligosaccharides. Preferably the composition according to the present invention includes galactooligosaccharide with SP from 2 to 10 and/or fructo-oligosaccharides with SP from 2 to 60. Galactooligosaccharide preferably selected from the group consisting of transplantationfollow, lacto-N-tetraone (LNT), lacto-N-neoteroi (neo-LNT), fucosyllactose, fokusirovannyi LNT and fokusirovannyi neo-LNT. In some preferred embodiments the embodiment of the present invention the method according to the present invention includes the introduction of transplantationfollow ([galactose]n-glucose; where n is an integer from 1 to 60, that is, 2, 3, 4, 5, 6,...., 59, 60; preferably n is chosen from the group 2, 3, 4, 5, 6, 7, 8, 9 or 10). Transplantological (CBT), for example, available under the trademark VivinalTM(Borculo Domo Ingredients, Netherlands). Before occhialino sugars of transplantationfollow are β-related. Fructooligosaccharide is a NDO, including chain β-linked fructose units with JV JV or middle from 2 to 250, more preferably from 10 to 100. Fructo-oligosaccharides include inulin, Levan and/or mixed type polifruktan. The most preferred fructooligosacharides is inulin. Fructooligosaccharide, suitable for use in the compositions of the present invention, also commercially available, for example, from Raftiline®HP (Orafti). Oligosaccharides, including uronic acid, preferably obtained in the degradation of pectin. Therefore, the composition of the present invention preferably includes the product of the degradation of pectin with SP from 2 to 100. Preferably the product of the degradation of pectin obtained from Apple pectin, beet pectin and/or citrus pectin. Preferably the composition includes transplantological, fructooligosaccharide and the product of the degradation of pectin. The mass ratio of transplantological:fructooligosaccharide:the product of the degradation of pectin is preferably (20-2):1:(1-3), more preferably (12-7):1:(1-2).

Lactose

Maintaining insulin sensitivity can be further enhanced by the inclusion in the composition of the present invention carbohydrates with a low glycemic index, preferably lactose. Sledovatel is but the composition according to the present invention preferably includes, in addition to present liquid lipid component is not digestible oligosaccharides and/or lactose. Therefore, the composition of the present invention preferably includes a component digestible carbohydrate, which comprises at least 35 wt.%, more preferably, at least 50 wt.%, more preferably at least 75 wt.%, even more preferably, at least 90 wt.%, most preferably at least 95 wt.% the lactose. Therefore, the composition of the present invention preferably contains at least 25 grams of lactose per 100 grams of the total dry weight of the composition, preferably at least 40 g lactose/100 grams.

Hydrolyzed protein

Preferably the composition includes hydrolyzed casein and/or hydrolyzed whey protein. It was found that the composition containing as a protein hydrolyzed casein and hydrolyzed whey protein, leading to lower levels of insulin and glucose after a meal compared with the introduction of a composition comprising intact intact casein and whey protein. Elevated levels of insulin and glucose indicate causation of insulin resistance with the introduction of the mixture is La infant feeding, what is believed, contributes to the development of obesity at a later stage of life. The composition according to the present invention preferably comprises at least 25 wt.% in terms of dry weight protein peptides with a chain length from 2 to 30 amino acids. The number of peptides with a chain length from 2 to 30 amino acids may be determined, for example, as described in Freitas et al., 1993, J. Agric. Food Chem. 41:1432-1438. The composition according to the present invention preferably contains hydrolyzed casein and/or hydrolyzed whey protein, more preferably hydrolyzed casein and hydrolyzed whey protein because the amino acid composition of casein in cow's milk is more similar to the amino acid composition found in milk protein, while protein and whey protein is easily digested and is found in greater proportion in the maternal milk. The composition according to the present invention preferably contains at least 50 wt.%, preferably, at least 80 wt.%, most preferably about 100 wt.% hydrolyzed protein, calculated on the total weight of protein. The composition according to the present invention preferably includes a protein with a degree of hydrolysis of protein from 5 to 25%, more preferably from 7.5 to 21%, most preferably from 10 to 20%. The degree of hydrolysis determine how interest is the ratio of peptide bonds, which were destroyed by enzymatic hydrolysis, from 100% of all potential peptide bonds.

Casein

Casein is mainly present, since it increases the time the evacuation of the stomach, forming a clot in the stomach, increasing, therefore, the feeling of fullness. Since the induction of satiety is very desirable, as above, the composition according to the present invention preferably includes casein. In the case when the composition is in liquid form, such as ready-to-use liquid form, the composition preferably comprises at least 0.5 g casein per 100 ml, preferably from 0.5 to 5 grams of casein per 100 ml. Preferably the composition comprises at least 4 wt.% casein in terms of dry substance. Preferably casein represents the intact casein and/or non-hydrolyzed casein.

Calcium

Preferably the composition includes calcium. The high content of dietary calcium reduces the concentration of intracellular calcium in fat cells that can reduce the differentiation of fat cells at a later stage and lipid filling. Preferably, the calcium is administered in terms of the carbonate, hydroxide, chloride, phosphate, lactate, gluconate, and/or citrate. Preferably the composition comprises at least 0.1 wt.% calcium is t total dry weight of the composition, preferably, at least 0.25 wt.%, most preferably at least 0.4 wt.%. Preferably the composition comprises less than 5 wt.% calcium by weight of the total dry matter of the composition, preferably less than 2 wt.%, more preferably less than 1 wt.%.

Nutrient composition

The composition of the present invention, particularly suited for providing the daily needs for nutrients an infant aged less than 36 months, in particular an infant aged less than 24 months, even more preferably under the age of 18 months, most preferably at the age of less than 12 months. Therefore, the composition according to the present invention includes a lipid component, a protein component and a component consisting of digestible carbohydrate, where the lipid component preferably provides from 35 to 55% of total calories, the protein component preferably provides from 5 to 15% of total calories and component consisting of digestible carbohydrate, preferably provides from 30 to 60% of your total calories. Preferably the composition includes a lipid component is from 40 to 50% of your total calories, the protein component provides from 6 to 12% of total calories, and a component consisting of digestible carbohydrate, provide ivaldi from 40 to 50% of your total calories. In the case when the composition is in liquid form, for example ready-to-use liquid, the composition preferably includes from 2.1 to 6.5 g of lipid per 100 ml, more preferably from 3.0 to 4.0 g per 100 ml of the Composition according to the present invention preferably contains from 12.5 to 40 wt.% lipid dry matter, more preferably from 19 to 30 wt.%.

The amount of saturated fatty acids is preferably less than 58 wt.% in terms of the total weight of fatty acids, more preferably less than 45 wt.%. The concentration of monounsaturated fatty acids is preferably in the range from 17% to 60%, calculated on the total weight of fatty acids. The composition of the present invention is not breast milk. The composition according to the present invention preferably includes (i) a vegetable lipid and/or animal (not breast milk) fat; and/or (ii) vegetable protein and/or animal (not breast milk) milk protein. Examples of animal milk protein is the protein of cow's milk and goat's milk protein. The composition according to the present invention preferably does not include an inhibitor of the protease, preferably trypsin inhibitor, chymotrypsin inhibitor or inhibitor of elastase. The composition of the present invention is not mother's milk.

The composition of the present invention predpochtite the flax contains, at least 50 wt.% protein derived from protein, not included in the composition of breast milk, in terms of the total weight of total protein, more preferably at least 90 wt.%. Preferably the composition according to the present invention contains at least 50 wt.% protein derived from cow's milk, in terms of the total weight of total protein, more preferably at least 90 wt.%. Preferably the composition according to the present invention contains an acidic and/or sweet serum with a low concentration of glycomacropeptides. Preferably, the composition according to the present invention includes a protein derived from β-casein and/or α-lactalbumin. Preferably the composition according to the present invention contains casein and whey protein in a weight ratio of casein:whey protein from 10:90 to 90:10, more preferably from 20:80 to 80:20. Used herein, the term "protein" refers to the amount of proteins, peptides and free amino acids. The composition according to the present invention preferably contains from 1.5 to 3.0 g protein/100 kcal, preferably from 1.8 to 2.25 g/100 kcal, more preferably from 1.8 to 2.0 g/100 kcal.

The composition of the present invention is preferably introduced in liquid form. In order to meet the requirements of the caloric requirements of the mixtures for infants, the composition preferably the includes from 50 to 200 kcal/100 ml of liquid, more preferably from 60 to 90 kcal/100 ml, even more preferably from 60 to 75 kcal/100 ml of liquid. Such caloric ensures the optimum balance between water consumption and calories. The osmolarity of the composition of the present invention is preferably from 150 to 420 mosmol/l, more preferably from 260 to 320 mosmol/L. Low osmolarity aimed at reducing stress in the gastrointestinal tract. The stress of the gastrointestinal tract can induce obesity.

Preferably the composition is in a liquid form having a viscosity below 35 centipoise, as measured on a Brookfield viscometer at a temperature of 20°C at a shear rate of 100 s-1. Accordingly, the composition is in powder form, which can be recovered water to a liquid form or in the form of a concentrated liquid that can be diluted with water.

In the case when the composition is in liquid form, the preferred volume for the daily injection is in the range from about 80 to 2500 ml, more preferably from about 450 to 1000 ml per day.

Baby

The fat cells of the baby, including visceral fat cells proliferate during the first 36 months of life, as well as in the pubertal period (more limited). The number of fat cells is an important determinant of the level is obesity at a later stage of life. Therefore, the composition of the present invention is administered to infants during the first 3 years of life. It was found that in the first 12 months of life is dominated by the proliferation of (visceral) fat cells (optimum perinatal proliferation). Therefore, particularly preferably the composition according to the present invention is the baby in this period of life. Therefore, the composition of the present invention is administered primarily to a person aged 0 to 24 months, more preferably to a person aged 0 to 18 months, most preferably to a person aged 0 to 12 months. In particular, the composition according to the present invention aims at the prevention of obesity at a later stage of life and preferably is not a treatment for obesity. Therefore, the composition of the present invention is preferably introduced the baby is not suffering from obesity or childhood obesity, more preferably baby without excess weight. The composition of the present invention is preferably administered to the infant oral.

Application

The composition of the present invention relates to a method for prevention of obesity in persons aged less than 36 months. Also, the present invention aims at preventing the occurrence of obesity in the age of 36 months who, in particular the prevention of obesity at the age of 8 years, in particular over 15 years, that is over the age of 18 years.

Preferably the composition is used for the prevention of obesity, more preferably common bariatric (obesity), because the total obesity is associated with various health disorders such as cardiovascular disease, hypertension and diabetes.

Herein and the claims, the verb "to include (contain)" and his shape should be interpreted in the open, not closed value if not explicitly stated otherwise. Used here and in the appended claims, the singular number include the plural, unless the context clearly is not visible otherwise. In addition, singular means at least one.

Examples

Example 1: Programming effects of dietary lipid on the formation of adipose tissue in adult

Offspring mice C57/BL6 distributed on nests on day 2 after birth to 6 pups (4M and 2ZH) female. Females received the experimental diet 2 days until weaning. The lipid composition of rat milk reflects the fat composition of the diet. After weaning mice males were kept in pairs on the experimental diets for 42 days, when the babies were switched to a diet containing the yard and additional cholesterol (1%).

We used the following experimental diets: 1) LC-PUFA diet (tuna fish oil); 2) a diet with a low LA, low ratio of LA/ALA (milk fat; low in canola oil with a high content of Trisun 80, without palm oil); 3) diet MCFA; 4) control diet (with the same amount of canola oil, coconut oil and palm oil). Fatty acid compositions of the diets are shown in Table 2. On day 42, all mice were transferred to the "fast food diet", consisting of 10 wt.% lipids (3 wt.% of lard and 1 wt.% cholesterol) by up to 98 days. Mice were weighed twice a week. During the experiment the amount of food consumed was determined 1 week. To determine body composition (i.e. fat mass (GM) and muscle mass (MM)) was performed DEXA scan (deenergizes x-ray absorbtiometry) under General anesthesia in 6-, 10 -, and 14 weeks of age, 42, 70 and 98 days after birth, respectively, for densiometry used the device for imaging PIXImus (GE Lunar, Madison, WI, USA). At the age of 14 weeks, male mice killed and plasma, epididymal fat, renal fat, pancreas, liver and kidney were prepared and weighed.

Results: during the experiment was observed effects on growth and on the amount of food consumed in the groups (data not shown). In addition, RA is the development of fat mass (defined DEXA) did not differ on day 42 (end of feeding the experimental diet). However, in the subsequent content on "fast funom" diet (high in saturated fatty acids) with 42 98 day in all groups, which differed from the results on the composition of the body tissues to the end of the experiment (day 98), see Table 3. Babies treated in early life diet with LC-PUFA, MCFA or low LA, low ratio of LA/ALA, has been reduced fat mass compared with calves fed the control diet. However, the rations at the initial period of life had a great impact on the distribution of body fat. It is seen that the ratio of subcutaneous:visceral fat (measured epididymal and renal fat, respectively) in adult mice at the age of 98 days was increased by 14% in the group treated with LC-PUFA, and 32% in the group receiving the diet with low content of LA, but was not increased in the group treated with MCFA, compared with the control group, see Table 3. This shows that visceral fat mass at a later stage of life is clearly reduced with the consumption of early life diet with a high content of LC-PUFA, and/or with low content of LA and/or low ratio of LA/ALA. So, we can conclude that the fat composition program and/or imprinted on the body, allowing you to get more healthy distribution of body fat at a later stage is isni. Thus, we can conclude that the fat composition program and/or imprinted on the body, allowing you to prevent obesity at a later stage of life.

0,00
Table 2
Fatty acid compositions of the diets
ControlMCFALC-PUFAlow containing of LA"fast food diet"
g/100 g fatg/100 g fatg/100 g fatg/100 g fatg/100g fat
C-4:00,000,000,001,050,00
C-6:00,110,150,070,810,06
C-8:0 1,7011,421,072,090,85
C-10:01,368,770,862,170,68
C-12:010,53of 1.346,6911,42to 5.57
C-14:0of 4.380,753,627,242,69
C-14:1w50,000,000,000,000,00
C-15:00,000,000,000,000,00
C-16:0 17,1413,3519,3812,4023,07
C-16:1w70,130,121,200,781,56
C-17:00,000,000,370,000,00
C-18:0of 3.072,393,705,129,03
C-18:1w937,9438,52of 35.2740,7940,47
C-18:2w6LA14,8014,3111,896,3811,90
C-18:3w3ALA2,6 2,611,07of 1.571,30
C-18:3w60,000,000,000,000,00
C-18:4w30,000,000,000,000,00
C-20:00,340,340,260,200,17
With-20:1w90,410,410,150,220,21
With-20:2w60,000,000,000,000,00
With-20:3w60,00 0,000,000,000,00
With-20:4w30,000,000,070,000,00
With-20:4w6AA0,000,000,280,000,00
With-20:5w3EPA0,000,001,200,000,00
C-22:00,230,280,240,330,11
C-22:1w90,140,140,050,080,07
C-22:4w60,000,000,000,00
C-22:5w3DPA0,000,000,370,000,00
C-22:6w3DHA0,000,005,000,000,00
C-24:00,020,020,020,000,01
C-24:1w90,000,000,000,000,00
Cholesterol1,00
total94,9194,9293,02 92,6698,46

Table 3
% fat of the total fat mass of the body over time and correlations between subcutaneous (epididymal) and total (renal) fat
DayThe control dietMCFA
diet
LC-PUFA dietDiet with low content of LA
Fat mass (%)4219,617,116,617,1
Fat mass (%)7022,122,8a 21.524,2
Fat mass (%)9826,922,820,924,2
The ratio of subcutaneous fat/
visceral fat
987,547,28,59 9,92
Growth ratio (%)-4%+14%+32%

Example 2: a Positive effect of phospholipids on insulin sensitivity

Nutrient composition: Complete infant formula above composition was injected phospholipids (0.2 g/100 ml) using a commercially available concentrate buttermilk/plasma oil Lactalis. As control was used the same mixture for baby food without the introduction of phospholipids. The concentration of phospholipids in experimental mixtures baby food amounted to about 6.3 wt.% from the total mass of lipids and about 0.75 wt.% from the total mass of lipids in the control mixture for baby food. The experimental arrangement consisted of about 1.4 wt.% sphingomyelin of the total mass of lipids and about 4 wt.% cholesterol from the total mass of lipids. In the control mixture for baby food number of sphingomyelin and cholesterol was negligible.

Methods: 20 adult male Wistar rats (aged 10 weeks at the beginning of the experiment) were held separately. 4 hours after feeding 10 animals were fed 2 ml of the composition. Three different compositions were tested in the cross-experiment (with a break between what xperimental 1 week): (i) Standard infant formula, ii) a Mixture of baby food, including phospholipids. Then blood samples (200 μm) were collected in hyperinationary chilled tubes through t=0, 5, 10, 15, 30, 60 after feeding. Then centrifugation was separated plasma (10 min, 5000 rpm) and kept at -20°C until analysis. The plasma insulin was measured using a radioimmunological assay (RIA from Linco Research)following the manufacturer's instructions with the following changes: all amounts analyses were reduced four times.

Results: The area of the curve of insulin (AUC) in rats fed an infant formula containing phospholipids, was lower than in rats fed standard infant formula (table 4). The introduction of a mixture of baby food, including a phospholipid, sphingolipid and/or cholesterol, has resulted in the afternoon levels of insulin and kinetics, more similar to those in maternal milk. Lower insulin levels indicate increased sensitivity to insulin, which presumably contributes to the prevention of obesity, particularly obesity at a later stage of life.

Table 4
The effect of phospholipids on the area of the curve afternoon insulin
InfluenceStandardPhospholipidsBreast milk
AUC10 (±SE)
insulin (PM*10 minutes)
AUC15 (±SE)
insulin (PM*15 minutes)
AUC30 (±SE)
insulin (PM*30 minutes)
AUC60 (±SE)
insulin (PM*60 minutes)
9,8±1,4
14,8±2,1
21,4±2,9
25,8±3,3
9,5±1,0
13,8±1,6
18,7±2,0
23,6±2,2
11,7±4,7

Example 3: Glucose/insulin blood and not digestible oligosaccharides

Animals and treatments adult male Wistar rats (n=7) as the fibers receive STATE, the cellulose or water via gastric tube in 1 day. Entered 6 ml bolus equivalent to 50%increase consumption of fiber a day; as the STATE of the fibers used transplantological available from Elix'or (Borculo Domo). Fibers were dissolved in water. After 24 hours (second day) conducted a test of tolerance to oral input glucose and afternoon glucose and insulin observed after 120 minutes after intragastric administration of carbohydrate (2 g/kg body weight). Then again in tubes took blood samples from the jugular vein. Intragastric administration of water or of a solution of cellulose in water in 1 day was used as control. Because the drug GOS fibers was 50% of the digestible carbohydrates(mainly lactose) to correct this when conducting 2 control introductions have also introduced carbohydrates.

Results: the preliminary introduction of STATE of the fibers is clearly reduces insulin secretion, resulting in a significant reduction (p<0,05) and the AUC. The blood glucose levels have changed slightly. The pretreatment of cellulose or water had no effect on insulin secretion, see Table 5.

Table 5
The levels of insulin and glucose in rats
Preliminary introduction:AUC insulin (PM*30 minutes)AUC glucose (RM*30 minutes)
Water41±769±10
Glucose46±875±9
STATE22±474±15

Example 4: a Mixture of baby food

The infant formula included lipid component, providing 48% of the total calories, the protein component, providing 8% of all calories, and a component consisting of digestible carbohydrates, providing 44% of total calories; (i) a lipid component comprising by weight of the total fatty acids: 14 wt.% LA; 2.6 wt.% ALA; 3.7 wt.% MCFA; 0.2 wt.% DHA; 0,05 wt.% EPA; 0.02 wt.% DPA; to 0.35 wt.% AA; 0.03 wt.% DHGLA. From the total body fat mass to the position consisted of about 0.75 wt.% soy phospholipids and > 0.005 wt.% cholesterol; (ii) a carbohydrate component comprising of 50.9 g lactose/100 grams powder; 5,22 g galactooligosaccharides JV 2-6 and of 0.58 g of fructo-oligosaccharides from LP 7-60; (iii) the protein component, including cow's milk protein, including casein. Additionally, the composition consisted of 73 mg of choline and 5.6 mg UMP per 100 g of dry matter. The composition consisted of 364 mg of calcium per 100 g of dry matter. The composition of the included vitamins and minerals in accordance with the requirements and recommendations of the EU. On the label of the packaging mix for baby food indicated that feeding prevents the development of obesity.

1. The use of a composition containing a lipid component, a protein component and a component consisting of digestible carbohydrates, where the lipid component includes:
(i) linoleic acid (LA) and alpha-linolenic acid (L) in a mass ratio of LA/L from 2 to 7;
(ii) less than the 14.5 wt.% LA in terms of the total weight of fatty acids;
and
(iii) from 2 wt.% to less than 10 wt.% L in terms of the total weight of fatty acids
and where the composition further comprises n-6 long-chain polyunsaturated fatty acids (line with an-UF) and n-3 line with an-UF mass ratio of less than 1.5; from 0.02 to 0.8 wt.% n-6 line with an-UF in terms of the total weight of fatty acid and from 0.2 wt.% up to 15 wt.% n-3 line with an-UF in terms of the total weight of fatty acids
to obtain the nutrient composition is, intended for the introduction of not suffering from obesity infant aged less than 36 months for the prevention of obesity.

2. The use according to claim 1, where the composition contains
(i) from 3 to 50 wt.% medium chain fatty acids (F), calculated on the total weight of fatty acids.

3. The use according to claim 1 or 2, where the composition comprises linoleic acid (LA) and alpha-linolenic acid (L) in a mass ratio of LA/L from 2 to 5.

4. The use according to claim 1 or 2, where the composition further comprises at least 0.5 wt.% at least one soluble not digestible oligosaccharide, calculated on the total weight of dry matter of the composition.

5. The use according to claim 1 or 2, where the composition contains at least 0.5 wt.%, at least one soluble not digestible oligosaccharide selected from the group consisting of fructo-oligosaccharides (including inulin), galactooligosaccharides (including transplantological), glucooligosaccharides (including gentoo, Niger and cyclodextringlucosyl), arabinopyranoside, mannanoligosaccharides, xylooligosaccharides, focalisation, arabinogalactans, glycogenolysis, galactopyranoside, oligosaccharides containing sialic acid and oligosaccharides, including uronic acid.

6. The use according to claim 1 or 2, where the composition contains the ha shall aktualisiere.

7. The use according to claim 1 or 2, where the composition further comprises fructo-oligosaccharides.,

8. The use according to claim 1 or 2 to prevent the development of obesity in later life stage and/or to prevent the development of obesity when the specified age of the child is more than 36 months.

9. The use according to claim 1 or 2, where the composition further comprises:
(a) from 0.5 to 20 wt.% phospholipids, calculated on the total weight of fat;
(b) from 0.5 to 20 wt.% of sphingolipids in terms of the total weight of fat;
(C) 0.005 to 10 wt.% cholesterol, calculated on the total weight of fat;
and/or
(d) from 0.035 to 1 wt.% choline, calculated on the total weight of dry matter of the composition and
from 0.001 to 0.1 wt.% uridine, calculated on the total weight of dry matter of the composition.

10. The use according to claim 1 or 2, where the lipid component provides 35 to 55% of total calories, the protein component provides 5 to 15% of total calories, and a component consisting of digestible carbohydrates, provides 30 to 60% of your total calories.

11. The use according to claim 1 or 2, where the composition provides 60-90 kcal/100 ml

12. The use according to claim 1 or 2 to prevent the development of obesity in people over the age of 12 years.

13. The use according to claim 1 or 2, where the nutritional composition is administered to infants aged less than 12 months.

14. The use according to claim 1 or 2, where the composition with the holds, at least 0.3 wt.% calcium, calculated on the total weight of dry matter of the composition.



 

Same patents:

FIELD: food industry.

SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases.

EFFECT: improvement of infant health without risks of adverse allergic reaction.

25 cl, 2 dwg, 3 tbl, 1 ex

FIELD: food industry.

SUBSTANCE: invention relates to a non-allergenic food product. The food product includes an amino acid fraction containing at least one component chosen from the group consisting of amino acids and peptides with a degree of polymerisation 7 or less, and a lipid fraction containing at least one fatty acid chosen from the group consisting of arachidonic acid and docosahexanoic acid. The composition content of protein and other peptides with molecular weight 1000 daltons or more (in relation to dry weight) is less than 0.01 wt %, preferably - no less than 0.001 wt %, more preferably - no less than 0.0001 wt %. The food product is used for allergy diagnostics.

EFFECT: invention allows to produce a product which does not impart allergic reactions and is able to attenuate intensity of the patients' allergic reactions.

7 cl, 4 ex

FIELD: food industry.

SUBSTANCE: invention relates to a nutritive composition, to application of the composition in a food product as a protein substitute, to a food supplement and a food product containing the said nutritive composition. The composition consists of particles containing a protein material and micronutrients; 90-100 wt % of the said protein material and micronutrients are coated with a fat-containing layer containing 90-100 wt % of a food fat of the total layer weight and having solid fat content in an amount of 70-100% at a temperature of 37°C.

EFFECT: nutritive composition has a neutral taste, scent, texture and long storage life; the composition is intended for patients suffering from food allergy or phenyl ketonuria.

7 cl, 4 ex

FIELD: food industry.

SUBSTANCE: invention relates to infant alimentation. One proposed application of fat, digestible carbohydrates and protein to produce a composition for therapy and/or prevention of adiposity as well as coexistent diseases. The protein includes at least 25 wt % of peptides with chain length from 25 to 30 amino acids (of total dry protein weight), the composition contains at least 12 mg of indigestible fermentable carbohydrates per 1 g of dry nutritious mixture weight. The composition is applied for baby feeding.

EFFECT: invention allows to prevent overgrowth and proliferation of adipcytes in the period of infancy (and, consequently, children's adiposity and secondary disturbances connected to it) due to combination of hydrolysed proteins and indigestible fermentable carbohydrates.

14 cl, 2 dwg, 1 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: this invention relates to application of at least one donor methyl group from the group of choline, methionine and betaine in a water-based drinking product immediately ready for consumption and to such a water-based drinking product immediately ready for consumption. In accordance with the invention concept, the drinking product contains a liquid food compound consisting of guanidinoacetic acid component and at least one donor methyl group from the group of choline, methionine and betaine.

EFFECT: addition of a methyl group donor selected from among choline, methionine and betaine, into the water-based drinking product immediately ready for consumption serves to increase the guanidinoacetic acid component stability.

11 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention is related to a food product for AIDS patients. Proposed is a food composition containing one or more acidic oligosaccharide(s) and one or more neutral oligosaccharide(s) and cysteine and/or a cysteine source. The acidic oligosaccharides are produced from pectin, pectate, alginate, chondroitin, hyaluronic acids, heparin, heparan, sialoglycanes, fucoidan, fucooligosaccharides or carageenan. The neutral oligosaccharides are selected from a group consisting of galactooligosaccharide, fructooligosaccharide, transgalactooligosaccharide, xylooligosaccharide, lactosucrose and arabinooligosaccharide where the said cysteine source is represented by N-acetylcysteine and/or diacetylcysteine, whey, beestings, egg whites or combination thereof.

EFFECT: invention enables preclusion and prevention of AIDS-related disfunctions.

12 cl, 1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention is related to alimentation, in particular - to a method and composition for improvement of glucose and insulin balance. Proposed is a compound that includes: a protein source, a fat source and a carbohydrate source, the protein source to the fat source ratio being approximately 1:1:1, each source accounting for 15% - 45% of the total calorie content of the compound. The fat source accounts for approximately over 2% of the total calorie content of the composition in the form of linoleic acid (18:2). According to an alternative version, the food compound for normalisation of insulin and glucose in the organism contains a protein source, a fat source and a carbohydrate source at a ratio of 1:1:1, each of these components accounting for approximately a third of the total calorie content of the compound. Additionally proposed are a diet for enhancement of sensitivity to insulin, a method to reduce resistivity to insulin, a method to reduce insulin levels in the plasma during after dinner time, a method to delay occurrence of insulin in one's blood and a method to increase fat clearance during after dinner time envisaging usage of the above food compound.

EFFECT: invention allows to improve glucose regulation and insulin effect.

68 cl, 34 dwg, 38 tbl

FIELD: food industry.

SUBSTANCE: invention relates to a nutritive supplement, to a method of its production and application. The nutritive supplement, according to the invention, contains a protein source including milk protein isolate and/or canola protein, a fat source, a carbohydrate source and water and has calorific value 2.25 - 3.25 cal/ml and viscosity lower than 120 centiPoise. The method for production of the supplement envisages a mixture preparation of water and the protein source, the fat source, the carbohydrate source, the mixture treatment with direct injection of vapour, the mixture homogenisation. The nutritive supplement, according to the invention, is applied in combination with one or more medicaments during therapy of nutritional deficiency. The nutritive supplement has high calorific value and will be useful for persons suffering from body weight loss.

EFFECT: milk protein isolate treatment with application of direct injection of vapour allows to reduce viscosity of the nutritive supplement.

20 cl, 4 tbl, 12 ex

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

Antioxidant complex // 2419362

FIELD: food industry.

SUBSTANCE: invention is related to food industry, in particular - to production of specialised products based on natural raw materials that may be used for alimentation of sportsmen as well as persons leading an active lifestyle. The antioxidant complex contains dihydroquercetin, L-carnozine, zinc citrate, selenopyran and vitamins A, C, E at a certain ratio. The invention enables reliable protection against multiple effects of oxidation and free radical impact.

EFFECT: maximally efficient dosage of the active components and absolutely accurately selected proportion of antioxidants in the formulated complex composition enable manifold intensification of the organism protective function and a significant cascade antioxidant action.

4 cl

FIELD: food industry.

SUBSTANCE: method of oligasaccharide mixture production from animal milk which has the same range of oligasaccharides as milk it was produced from includes the following stages: (a) concentration of deproteines milk material to the total content of dry substance from 50 to 75% given the condition that temperature shall not rise to the level at which hydrolisis or sialic acid reduction take place; (b) concentrated milk is subject to partial lactose removal and preparation of solution with lactose: oligasaccharide ratio less than 250, and (c) demineralization of milk material - at this the stage of demineralization is conducted either before concentration stage or after lactose removal. Also invention refers to the mixture of oligasaccharides recieved this way from animal milk and food products containing the mentioned mixture of oligasaccharides.

EFFECT: receipt of mixture of oligasaccharides.

18 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention is referred to the area of medicine, namely to hematology, endocrinology and cardiology and can be used for decease of spontaneous RBC aggregation in patients with abdominal obesity. To do that the metformin infusion are performed with the background of hypocaloric diet and dosed static and dynamic physical exercises. Physical exercises include morning hygiene gymnastics, therapeutic gymnastics, single physical exercises during the day, daily swimming for no less than 30 minutes a day in the middle of the day. Metformin is given in the dose 500 mg twice a day. The treatment shall be performed for 1 month.

EFFECT: method provides for normalization of spontaneous RBC aggregation within 1 month, bringing it down on the level close to that in healthy people and thus decreasing the risk of thrombotic complications in patients with abdominal obesity.

2 ex, 1 dwg

FIELD: food industry.

SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases.

EFFECT: improvement of infant health without risks of adverse allergic reaction.

25 cl, 2 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and can be used for treating hyperplastic endometrial processes in patients with metabolic syndrome. A method involves enzyme immunoassay of blood serum to determine a progesterone level, and if its concentration is 8.0 nmol/l and higher, metabolic therapy including administration of methphormin 1000 mg × 2 times a day, hypo-calorie diet with calorage limited to 1500 kcal a day and increased physical activity in the form of intensive walking. The progesterone concentration lower than 8.0 nmol/l requires additionally another enzyme immunoassay of blood serum to evaluate a leptin level, and if its value is lower than 57.18 ng/ml, the metabolic therapy described above is prescribed. If the leptin level exceeds 57.18 ng/ml, the patients require a combined metabolic and hormonal therapy consisting in administration of methphormin 1000 mg × 2 times a day, dufaston 10 mg × 2 times a day starting with the 16th for 25th day of a menstrual cycle, hypo-calorie diet with calorage limited to 1500 kcal a day and graduated physical activity in the form of walking starting with 10 minutes to be gradually increased to 40 minutes in day.

EFFECT: method allows preserving the reproductive function.

1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.

EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.

12 cl, 5 tbl, 6 ex

FIELD: food industry.

SUBSTANCE: invention relates to a non-allergenic food product. The food product includes an amino acid fraction containing at least one component chosen from the group consisting of amino acids and peptides with a degree of polymerisation 7 or less, and a lipid fraction containing at least one fatty acid chosen from the group consisting of arachidonic acid and docosahexanoic acid. The composition content of protein and other peptides with molecular weight 1000 daltons or more (in relation to dry weight) is less than 0.01 wt %, preferably - no less than 0.001 wt %, more preferably - no less than 0.0001 wt %. The food product is used for allergy diagnostics.

EFFECT: invention allows to produce a product which does not impart allergic reactions and is able to attenuate intensity of the patients' allergic reactions.

7 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy, reflexology. Method includes introduction of low-calorie diet. Simple carbohydrates are limited to 10% of calorie content, general fats - to 30-35% of calorie content, animal fats - to 10%. Diet is enriched with proteins to 25%, vitamins, minerals, with magnesium - to 500 mg, cellulose - to 30 g. If body weight index is 25-30 units, food calorie content is limited to 1800 kcal per day for men and 1500 kcal - for women, course of auricular acupuncture is carried out. Course includes carrying out 10 sessions for 30 minutes in points AP 17 and AP 18. If body weight index is higher than 30, food calorie content is limited to1500 kcal for men and 1400 kcal - for women. Additionally to auricular acupuncture after 20-30 days carried out are 10 30-minute long procedures of corporal acupuncture every second day or daily. Corporal acupuncture is performed in points of intersection of anterior, medial and posterior axillary lines with horizontal line, drawn through crests of iliac bones.

EFFECT: method ensures body weight correction without application of drug therapy, does not have side effects.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology and cardiology, and can be used for reduction of spontaneous aggregation of erythrocytes in case of arterial hypertension with dyslipidemia and disturbance of tolerance to glucose. For this purpose at the background of hypolipidemic diet, dosed static and dynamic physical exercise and daily swimming for not less than 30 minutes per day in the middle of the day introduced are lisinopril and metformin. Physical exercise includes morning hygienic gymnastics, therapeutic-preventive gymnastics, fractional physical exercise throughout the day. Lisinipril is introduced in dose 10 mg 1 time per day in the morning. Metformin is introduced in dose 500 mg 2 times per day. Treatment is carried out for 2 months.

EFFECT: method makes it possible to normalise spontaneous aggregation of erythrocytes during 2 months, bringing it to the level close to the level of healthy people, which in its turn contributes to reduction of risk of thrombotic complications.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology and cardiology, and can be used for reduction of spontaneous aggregation of erythrocytes in case of arterial hypertension with abdominal obesity and disturbance of tolerance to glucose. For this purpose at the background of hypocalory diet, dosed static and dynamic physical exercise and daily swimming for not less than 30 minutes per day in the middle of the day introduced are lisinopril and metformin. Physical exercise includes morning hygienic gymnastics, therapeutic-preventive gymnastics, fractional physical exercise throughout the day. Lisinipril is introduced in dose 10 mg 1 time per day in the morning. Metformin is introduced in dose 500 mg 2 times per day. Treatment is carried out for 2 months.

EFFECT: method makes it possible to normalise spontaneous aggregation of erythrocytes during 2 months, bringing it to the level close to the level of healthy people, thus contributing to prevention of vascular complications in patients with arterial hypertension with abdominal obesity and with disturbance of tolerance to glucose.

2 ex

FIELD: food industry.

SUBSTANCE: present invention relates to a food additive to be administered to children. Alternatively, the food additive contains a protein source, a source of vitamins and minerals, a carbohydrates source as well as a lipids source including a source of docosahexaenoic acid, linoleic and linolenic acids. The ratio of ω-6:ω-3 fatty acids in the said food additive is 6:1 or less. Alternatively, the food additive contains protein, carbohydrate and lipid components; the lipid component includes 10% - 50% of canola oil, 5% - 40% of soybean oil, 5% - 40% of high-oleic sunflower oil, 5% - 40% of middle chain triglyceride oil, 1% - 20% of corn oil and 0.1% - 10% of a docosahexaenoic acid source.

EFFECT: food additive having a ratio of ω-6:ω-3 of fatty acids 6:1 and less improves the immune system functions, the heart-vascular system activity, bone tissue quality and has a favourable effect on mental processes.

14 cl, 9 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: method of oligasaccharide mixture production from animal milk which has the same range of oligasaccharides as milk it was produced from includes the following stages: (a) concentration of deproteines milk material to the total content of dry substance from 50 to 75% given the condition that temperature shall not rise to the level at which hydrolisis or sialic acid reduction take place; (b) concentrated milk is subject to partial lactose removal and preparation of solution with lactose: oligasaccharide ratio less than 250, and (c) demineralization of milk material - at this the stage of demineralization is conducted either before concentration stage or after lactose removal. Also invention refers to the mixture of oligasaccharides recieved this way from animal milk and food products containing the mentioned mixture of oligasaccharides.

EFFECT: receipt of mixture of oligasaccharides.

18 cl, 2 tbl, 3 ex

Up!